Founded by nanoparticle and drug-delivery researchers, Pittsburgh-based Duo Oncology is a clinical-stage biotechnology company developing tumor-activated medicines for cancer treatment. Its lead program, DUO-207, is designed to simplify chemotherapy by concentrating drug activity in tumors while reducing exposure in healthy tissue.
FDA Orphan Designation
Predictive OncologyPittsburgh-based Predictive Oncology uses machine learning, human tumor data and laboratory models to support oncology drug discovery and clinical treatment decisions. Its proprietary platform draws on a privately held biobank of more than 150,000 tumor samples, while its CLIA-certified Helomics laboratory provides tumor drug-response and genomic testing alongside research support for biopharmaceutical developers.PITTSBURGH, PA
Facili Bio LLCFacili Bio LLC uses an AI-powered drug-discovery platform and proprietary computational biology to develop new cancer treatments. The company focuses on difficult areas of oncology, pairing research into patient-specific therapies with clinical studies intended to move promising discoveries toward patients.ALBANY, NY
BeyondSpringFounded in 2010, BeyondSpring is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies, centered on its investigational lead asset Plinabulin. The Florham Park company is advancing Plinabulin as a GEF-H1 agonist that promotes dendritic-cell maturation and may help re-sensitize tumors after checkpoint-inhibitor treatment while reducing chemotherapy-induced neutropenia. Its development program has treated more than 700 cancer patients and includes the confirmatory DUBLIN-4 Phase 3 program in non-small-cell lung cancer.NEW YORK, NY
Modulation TherapeuticsFounded in 2011 as a Moffitt Cancer Research Center spinoff, Modulation Therapeutics is a Morgantown clinical-stage biotechnology company developing therapies for aggressive solid-tumor cancers and liver disease. Its research team combines targeted alpha radiotherapy with peptide and small-molecule drug development, including a therapy for metastatic melanoma that has received FDA Orphan Drug and Fast Track designations. The privately held company moved its primary operations to West Virginia in 2016 and works with West Virginia University researchers to advance its pipeline toward clinical use.MORGANTOWN, WV